Low-dose MTX combined with low-dose methylprednisolone as a first-line therapy for the treatment of acute GVHD: Safety and feasibility

Bone Marrow Transplantation

Volumn 46, Issue 6, 2011, Pages 892-898

  Wang, Y ^a   Xu, L P ^a   Liu, K Y ^a   Liu, D H ^a   Wang, J ^a   Chen, H ^a   Chen, Y H ^a   Han, W ^a   Huang, X J ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

acute GVHD; methylprednisolone; MTX

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DACLIZUMAB; HYDROXYUREA; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SEMUSTINE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; LOW DRUG DOSE; MALE; MYELODYSPLASTIC SYNDROME; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIMETABOLITES, ANTINEOPLASTIC; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DRUG TOXICITY; FEMALE; GRAFT VS HOST DISEASE; HUMANS; MALE; METHOTREXATE; METHYLPREDNISOLONE; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79958177304     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.197     Document Type: Article

References (19)

1. Greinix HT, Volc-Platzer B, Rabitsch W, Gmeinhart B, Guevara-Pineda C, Kalhs P et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 1998; 92: 3098-3104. (Pubitemid 28492315)
2. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
3. Deeg HJ. How I treat refractory acute GVHD. Blood 2007; 109: 4119-4126. (Pubitemid 46743372)
4. Mielcarek M, Storer BE, Boeckh M, Carpenter PA, McDonald GB, Deeg HJ et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood 2009; 113: 2888-2894.
5. Bertz H, Afting M, Kreisel W, Duffner U, Greinwald R, Finke J. Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD. Bone Marrow Transplant 1999; 24: 1185-1189. (Pubitemid 30021210)
6. McDonald GB, Bouvier M, Hockenbery DM, Stern JM, Gooley T, Farrand A et al. Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial. Gastroenterology 1998; 115: 28-35. (Pubitemid 28307284)
7. VanLint MT, Uderzo C, Locasciulli A, Scimé R, Locatelli F, Giorgiani G et al. Early treatment of acute graft-versus-Host disease with high- or low-dose 6-methylprednisolone: a multi-center randomized trial from the italian group for bone marrow transplantation. Blood 1998; 92: 2288-2293. (Pubitemid 28452969)
8. Hings IM, Filipovich AH, Miller WJ, Blazar BL, McGlave PB, Ramsay NK et al. Prednisone therapy for acute graft-versus-host disease: short- versus long-term treatment: a prospective randomized trial. Transplantation 1993; 56: 577-580. (Pubitemid 23293018)
9. Huang XJ, Jiang Q, Chen H, Xu LP, Liu DH, Chen YH et al. Low-dose methotrexate for the treatment of graft versus host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2005; 36: 343-348. (Pubitemid 41195168)
10. Wang Y, Xu LP, Liu DH, Chen H, Chen YH, Han W et al. First-line therapy for chronic graft-versus-host disease that includes low-dose methotrexate is associated with a high response rate. Biol Blood and Marrow Transplant 2009; 15: 505-511.
11. Chen YH, Huang XJ, Xu LP, Liu DH, Chen H, Zhang YC et al. A comparative study of peripheral blood stem cell vs bone marrow transplantation from unrelated donors. Chin Int Med 2006; 45: 624-627.
12. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W et al. Haplo-identical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006; 38: 291-297. (Pubitemid 44203779)
13. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W et al. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant 2009; 15: 257-265.
14. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
15. Martin PJ, Nelson BJ, Appelbaum FR, Anasetti C, Deeg HJ, Hansen JA et al. Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Blood 1996; 88: 824-830. (Pubitemid 26333302)
16. Bertz H, Afting M, Kreisel W, Duffner U, Greinwald R, Finke J. Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD. Bone Marrow Transplant 1999; 24: 1185-1189. (Pubitemid 30021210)
17. Johnston A, Gudjonsson JE, Sigmundsdottir H, Ludviksson BR, Valdimarsson H. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 2005; 114: 154-163. (Pubitemid 40082381)
18. Inagaki J, Nagatoshi Y, Hatano M, Isomura N, Sakiyama M, Okamura J. Low-dose MTX for the treatment of acute and chronic graft-versus-host disease in children. Bone Marrow Transplantation 2008; 41: 571-577. (Pubitemid 351472149)
19. de Lavallade H, Mohty M, Faucher C, Fürst S, El-Cheikh J, Blaise D. Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. Haematologica 2006; 91: 1438-1440. (Pubitemid 44569831)